Team:UCSF/Parts

From 2010.igem.org

(Difference between revisions)
 
(6 intermediate revisions not shown)
Line 32: Line 32:
{
{
margin-left:35px;
margin-left:35px;
-
width:80%;
+
width:75%;
border-collapse:collapse;
border-collapse:collapse;
}
}
Line 60: Line 60:
<body>
<body>
-
<h3  style="font-weight:bold;">Parts</h3>
+
<h3  style="font-weight:bold;">Parts submitted to the Registry</h3>
</body>
</body>
</html>
</html>
Line 69: Line 69:
<!-- add device list below -->
<!-- add device list below -->
-
<table id="customers">
+
<p>During the summer we built more than 60 devices under the BioBrick standard <a href="https://2009.igem.org/Judging/Variance/UCSF" target="_blank">RFC28</a> (see more info <a href="http://dspace.mit.edu/bitstream/handle/1721.1/46721/BBFRFC28.pdf" target="_blank">here</a>), which was developed by the UCSF team in 2009 and was approved by the Registry of Parts.  However, this year the Registry does not accept RFC28.  Due to time constrains, we could not move all of these parts into pSB1C3 and submit them as we had planned.</p><br>
-
<tr>
+
-
  <td>Designed by</td>
+
-
  <td>Ligated parts</td>
+
-
  <td>Function</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>Old antiMesoCAR-LFA1-Dap10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
<!--  
-
  <td>John</td>
+
-
  <td>antiCD19CAR-DAP10-STOP</td>
+
-
  <td>Positive Control</td>
+
-
</tr>
+
 +
<table id="customers">
  <tr>
  <tr>
-
   <td>Hannah</td>
+
   <th>Designed by</th>
-
   <td>antiCD19CAR-mDAP10y85F-STOP</td>
+
   <th>Ligated parts</th>
-
   <td colspan=2>Stronger Signaling</td>
+
   <th>Function</th>
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiCD19CAR-mDAP10N87Q-STOP</td>
+
-
  <td>Negative Control</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Sam</td>
+
-
  <td>antiMESOCAR-mDAP10N87Q-STOP</td>
+
-
  <td>Logic Gate Signaling</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-DAP10-CD3Z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR- LFA1-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-DAP10-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Sam</td>
+
-
  <td>antiCD19CAR-DAP10-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Sam</td>
+
-
  <td>antiCD19CAR-DAP10-Dap10</td>
+
-
  <td colspan=2>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Sam</td>
+
-
  <td>antiCD19CAR-CD3z-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
  </tr>
  </tr>
  <tr>
  <tr>
   <td>Carmen</td>
   <td>Carmen</td>
-
   <td>antiMESOCAR-CD3Z-STOP</td>
+
   <td>device</td>
-
   <td>Positive Control</td>
+
   <td>purpose</td>
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiCD19-CD3z-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiMESOCAR-KIR3DL2-STOP</td>
+
-
  <td>Inhibition</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiCD19CAR-KIR3DL2-STOP</td>
+
-
  <td>Inhibition</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR -LFA1 -DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-mDAP10 M88Q-STOP</td>
+
-
  <td>Logic Gate Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiCD19CAR-mDAP10 M88Q-STOP</td>
+
-
  <td>Logic Gate Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiMESOCAR-OX40-Dap10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiMESOCAR-OX40-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
  <td></td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiMESOCAR-FcRg-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
  <td></td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiMESOCAR-ICOS-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiCD19CAR-FcRg-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
  </tr>
  </tr>
-
  <tr>
+
  <tr class="alt">
-
  <td>Carmen</td>
+
-
  <td>antiCD19CAR-ICOS-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiCD19CAR-LFA1-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-CD3z-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiMESOCAR-mDAP10Y85F-STOP</td>
+
-
  <td >Logic Gate Negative Control</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Connor</td>
+
-
  <td>antiCD19CAR-KIR3DL1-STOP</td>
+
-
  <td>Inhibition</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Connor</td>
+
-
  <td>antiMESOCAR-KIR3DL1-STOP</td>
+
-
  <td>Inhibition</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-DAP10-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiCD19CAR-OX40-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiCD19CAR-OX40-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
 
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiCD19CAR-SLAMF1-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiCD19CAR-SLAMF1-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Carmen</td>
+
-
  <td>antiCD19CAR-SLAMF5-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
   <td>John</td>
   <td>John</td>
-
   <td>antiMESOCAR-SLAMF1-CD3z</td>
+
   <td>device</td>
-
   <td>Stronger Signaling</td>
+
   <td>purpose</td>
-
</tr>
+
-
<tr>
+
-
  <td>John</td>
+
-
  <td>antiMESOCAR-SLAMF5-DAP10</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiCD19CAR-FcRg-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiCD19CAR-ICOS-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiCD19CAR-CD28-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
  </tr>
  </tr>
 +
 +
</table>
-
<tr>
+
-->
-
  <td>Lianna</td>
+
-
  <td>antiMESOCAR-FcRg-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiMESOCAR-ICOS-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiMESOCAR-CD28-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiCD19CAR-LFA1-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Lianna</td>
+
-
  <td>antiMESOCAR-LFA1-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiCD19CAR-LFA1-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-OX40-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-SLAMF3-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR- CD3g-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-Ly49-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiMESOCAR-NKG2A-STOP</td>
+
-
  <td>Negative Feedback</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiCD19CAR-OX40-STOP</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiCD19CAR-SLAMF3-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td> antiCD19CAR-CD3g-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
 
+
-
<tr>
+
-
  <td>Crystal</td>
+
-
  <td>antiCD19CAR-FcRg-CD3z</td>
+
-
  <td>Stronger Signaling</td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMB-eGFP-CDMPR</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMB-eGFP-GILT</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMB-eGFP-LAMP</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMB-eGFP-LIMP</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMB-eGFP-Ymotif</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMB-eGFP-STP</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMM-eGFP-CDMPR</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMM-eGFP-GILT</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMM-eGFP-LAMP</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMM-eGFP-LIMP</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMM-eGFP-Ymotif</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
<tr>
+
-
  <td>Min</td>
+
-
  <td>GZMM-eGFP-STP</td>
+
-
  <td>Localization to Cytoxic Granules </td>
+
-
</tr>
+
-
</table>
+
 +
<br>
 +
<br>
 +
<br>
<!-- content ends here -->
<!-- content ends here -->

Latest revision as of 22:29, 15 November 2010


Parts submitted to the Registry

<groupparts>iGEM010 UCSF</groupparts>

During the summer we built more than 60 devices under the BioBrick standard RFC28 (see more info here), which was developed by the UCSF team in 2009 and was approved by the Registry of Parts. However, this year the Registry does not accept RFC28. Due to time constrains, we could not move all of these parts into pSB1C3 and submit them as we had planned.





Retrieved from "http://2010.igem.org/Team:UCSF/Parts"